New epidemiologic patterns and risk factors in renal cancer;Nuevos patrones epidemiológicos y factores de riesgo en cáncer renal

Actas Urologicas Espanolas

Volumn 33, Issue 5, 2009, Pages 459-467

  Anglada Curado, Francisco J ^a   Hernández, Pablo Campos ^a   Castro, Rafael Prieto ^a   Carazo Carazo, José L ^a   Regueiro López, Juan C ^a   Jiménez, Francisco Vela ^a   Requena Tapia, Ma José ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Epidemiology; Renal cancer; Risk factors

Indexed keywords

EID: 67650720001     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(09)74178-6     Document Type: Review

References (70)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology. 2007;18(3):581-592.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statitics, 2006. A cancer Journal for Clinicians. 2006; 56(2):106-130.
3. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Robin s Sadler G. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179(5): 1704-1708.
4. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 2008;54(1):133-140.
5. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628-1631.
6. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol; 2008: art ID 782381.
7. Mathew A, Devesa SS, Fraumeni JF, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev. 2002;11(2):171-178.
8. Hock LM, Lynch J, Balaji KC. Incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis for Surveillance, Epidemiology and End Results program data. J Urol. 2002;167(1):57-60.
9. Kane CJ, Mallin K, Ritchey J, Coopenberg MR, Carroll P. Renal Cell Cancer Stage Migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78-83.
10. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol. 2008;179(5):1709-1713.
11. Levi F, Ferlay J, Galeone C, Lucchino F, Negri E, Boyle P, et al. The changing pattern of kideny cancer incidence and mortality in Europe. BJU Int. 2008;101(8):949-958.
12. Lopez-Abente G, Pollan M, Aragones N, Perez-Gomez B, Llácer A, Pérez J, et al.: Tendencias de la mortalidad en España, 1952-1996. Efecto de la edad, de la cohorte de nacimiento y del periodo de muerte Madrid. Instituto de Salud Carlos III;.2002.
13. Gonzalo López-Abente, Rebeca Ramis, Marina Pollán, Nuria Aragonés, Beatriz Pérez-Gómez, Diana Gómez-Barroso, José Miguel Carrasco, Virginia Lope-Carvajal, Javier García-Pérez, Elena Boldo, María José García-Mendizábal. Atlas Municipal de mortalidad por cácner en España, 1989-1998. 2007. Instituto de Salud CarlosIII.www.iscii.es/htdocs/centros/epi-demiologia/libros.
14. Gonzalo López-Abente, Nuria Aragonés, Beatriz Pérez-Gómez, Rebeca Ramis, Enrique Vidal, Javier García-Pérez, Pablo Fernández-Navarro and Marina Pollán. Kidney cancer mortality in Spain: geographic patterns and possible hypotheses. BMC Cancer 2008;8:293.
15. Garcia-Perez J, Boldo E, Ramis R, Pollan M, Perez-Gomez B, AragonesN, Lopez-Abente G: Description of industrial pollution in Spain. BMC Public Health 2007, 7:40.
16. Setiawan VW, Stram DO, Nomura AM et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007; 166: 932-940.
17. Loren Lipworth, Robert E Tarone, J K McLaughin. The epidemiology of renal cell carcinoma. The Journal of Urology. 2006; 176(6):2353-2358.
18. Wong-Ho Chow, Susan S. Devesa. Contemporary Epidemiology of Renal Cell Cancer. The Cancer Journal. 2008 14: 288-301.
19. Jay D. Hunt, Olga L. van der Hel, Garnett P. McMillan, Paolo Boffetta and Paul Brennan. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int. J. Cancer 2005 114:101-108.
20. Sharifi N, Farrar WL. Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation?. Med Hypotheses. 2006;66(4):732-735.
21. Zhu Y, Horikawa Y, Yang H, Wood CG, Habuchi T, Wu X.. BPDE Induced Lymphocytic Chromosome 3p Deletions May Predict Renal Cell Carcinoma Risk. J Urol. 2008;179(6):2416-2421.
22. Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, Frederiksen K, Tjønneland A, Rohrmann S, et al. The effect of occasional smoking on smoking-related cancers: in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2006;17(10):1305-1309.
23. Hu J, Ugnat AM, Canadian Cancer Registries Epidemiology Research Group. Active and passive smoking and risk of renal cell carcinoma in Canada. Eur J Cancer. 2005;41(5):770-778.
24. Parker AS, Cerhan JR, Janney CA, Lynch CF, Cantor KP. Smoking cessation and renal cell carcinoma. Ann Epidemiol. 2003;13(4):245-251.
25. Bretan PN, Busch MP, Hricak H, Williams RD. Chronic renal failure. A significant risk factor in the development of acquired renal cysts and renal cell carcinoma. Cancer. 1986;57(9):1871-1879.
26. Ishikawa I. Uremic acquired renal cystic disease. Natural History and complications. Nephron. 1991;58(3):257-267.
27. Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, et al. Cancers of the Kidney and Urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe and Australia and New Zealand. J Am Soc Nephrol. 2003;14(1):197-207.
28. Akizawa T, Kinugasa E, Koshikawa S. Increased risk of malignancy and blood-membrane interactions in uraemic patients. Nephrol Dial Transplant. 1994;9 Suppl 2:162-164.
29. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long term transplants. Transplantation. 1995;59(12):1705-1709.
30. Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc Nutr Soc. 2008;67(2):128-145.
31. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. N Engl J Med. 2003;348(17):1625-1638.
32. Wolk A, Gridley G, Niwa S, Lindblad P, McCredie M, Mellemgaard A, et al. International renal-cell cancer study, VII. Role of diet. Int J Cancer. 1996;65(1):67-73.
33. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidenceof cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.
34. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166(8):932-940.
35. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. The Journal of Urology. 2006;176(6 Pt 1): 2353-2358.
36. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476-2481.
37. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83.
38. Zigeuner R. Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney. Eur Urol. 2008;54 (4): 873-874.
39. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol.2000;27(2):115-123.
40. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sørensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005;92(7):1302-1306.
41. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, andthe risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305-1311.
42. McCredie M, Pommer JK, McLaughin JH, Stewart JH, Lindblad P, Mandel JS, et al. International renal cell cancer study II. Analgesics. Int J Cancer. 1995;60(3):345-349.
43. Rosemberg L, Rao RS, Palmer JR, Strom BL, Zauber A, Warshauer ME, et al. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control. 1998;9(1):83-88.
44. Sali D, Boffetta P. Kidney cancer and occupational exposure to asbestos: a meta-analisis of occupational cohort studies. Cancer Causes Control. 2000;11(1):37-47.
45. Lohi J, Kyyrönen P, Kauppinen T, Kujala V, Pukkala E. Occupational exposure to solvents and gasoline and risk of cancers in the urinary tract among Finnish workers. Am J Ind Med. 2008;51(9):668-672.
46. Wong O, Trent L, Harris F. Nested case control study of leukemia, multiple myeloma and kidney cancer in a cohort of petroleum workers exposed to gasoline. Occup Environ Med. 1999;56(4):217-221.
47. Lewis RJ, Schnatter AR, Drummond N, Murray FS, Thompson FS, Katz AM, et al. Mortality and cancer morbidity in a cohort of canadian petroleum workers. Occup Environ Med. 2003;60(12):918-928.
48. Raaschou-Nielsen O, Hansen J, McLaughlin JK, Kolstad H, Christensen JM, Tarone RE, et al. Cancer risk among workers at Danish companies using trichloroethylene: a cohort study. Am J Epidemiol. 2003;158(12):1182.
49. Charbotel B, Fevotte J, Martin JL, Bergeret A. Renal cell carcinoma and exposure to trichloroethylene: Are French occupational exposure limits relevant?. Rev Epidemiol Sante Publique. 2009;57(1):41-47.
50. Charbotel B, Fevotte J, Hours M, Martin JL, Bergeret A. Case control study on renal cell cancer and occupacional exposure to trichloroethylene. Part II: epidemiological aspects. Ann Occup Hyg. 2006;50(8):777-787.
51. Karami S, Boffetta P, Rothman N, Hung RJ, Stewart T, Zaridze D, Navritalova M, Mates D, Janout V, Kollarova H, Bencko V, Szeszenia-Dabrowska N, Holcatova I, Mukeria A, et al. Renal cell carcinoma, occupational pesticide exposure and modification by glutathione S-transferase polymorphisms. Carcinogenesis. 2008;29(8):1567-1571.
52. Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol. 2004;14(4):229-233.
53. Hu J, Mao Y, White K; Canadian Cancer Registries Epidemiology Research Group.. Diet and vitamin or mineral supplements and risk of renal carcinoma in Canada. Cancer Causes Control. 2003:14(8):705-714.
54. Lee JE, Spiegelman D, Hunter DJ, Albanes D, Bernstein L, van den Brandt PA, et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst. 2008;100(23):1658-1659.
55. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007; 99(10):801-810.
56. Dong C, Hemminski K. Modification of cancer risks in offsprings by siblings and parental cancers from 2112616 nuclear families. Int J Cancer. 2001;92(1):144-150.
57. Karami S, Brennan P, Hung RJ, Boffetta P, Toro J, Wilson RT, et al. Vitamin D receptor polymorphirms and renal cancer risk in Central and Eastern Europe. J Toxicol Environ Health. 2008;71(6):367-372.
58. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317-1320.
59. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppresor gene. Human Mutation. 1998;12(6):417-423.
60. Cohen HT, McGovern FJ. Renal-Cell Carcinoma. N Engl J Med. 2005;353(23):2477-2490.
61. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature.1999;399(6733):271-275.
62. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275(33):25733-25741.
63. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumorgrowth. PLoS Biol 2003;1(3):E83.
64. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of Von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726-4734.
65. Zbar B, Glenn G, Lubensky I, Choyke P, Walther MM, Magnusson G, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol. 1995;153(3 Pt 2):907-912.
66. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, et al. Duplication and overexpression of themutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene. 1998;17(6):733-739.
67. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA. 2001;98(6):3387-3392.
68. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406-410.
69. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar C, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002;26(12):1542-1552.
70. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2(2):157-164.